Entrada Therapeutics (TRDA) Q1 2024 Earnings
TRDA·Reported May 7, 2024·Before market open
Entrada Therapeutics reported Q1 2024 revenue of $59.1M, beat analyst consensus of $15.0M by $44.1M. Diluted EPS came in at $0.68, beat the $-0.59 consensus by $1.27.
Revenue
$59.1Mbeat by $44.1M
Consensus: $15.0MDiluted EPS
$0.68beat by $1.27
Consensus: $-0.59
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Entrada Therapeutics's Q1 2024 earnings report.
Entrada Therapeutics (TRDA) reported Q1 2024 earnings on May 7, 2024 before market open.
Entrada Therapeutics reported revenue of $59.1M and diluted EPS of $0.68 for Q1 2024.
Revenue beat the consensus estimate of $15.0M by $44.1M. EPS beat the consensus estimate of $-0.59 by $1.27.
You can read the 10-Q periodic report (0001689375-24-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.